ITRM — Iterum Therapeutics PLC

Iterum Therapeutics PLC (ITRM) is a biotechnology company listed on NASDAQ. It is led by Corey N. Fishman, based in 3 Dublin Landings, Dublin, Ireland, D01 C4E0, with about 9 employees. Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Latest reported ITRM revenue for 2025-09-30 was $390.0K. Net income was -$20.4M. ITRM currently screens at market cap $38.6M.

Use this ITRM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ITRM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ITRM SEC filings page. Lician reads the product cache first so this HTML stays unique to Iterum Therapeutics PLC even when a live quote feed is slow.